# EDGAR Filing Document

**Accession Number:** 0000882095
**File Stem:** 0001308179-23-000324
**Filing Date:** 2023-3
**Character Count:** 7697
**Document Hash:** bb5a5268ebf3426d6b6acee5bcf7a263
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001308179-23-000324.hdr.sgml**: 20230323

**ACCESSION NUMBER**: 0001308179-23-000324

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 11

**FILED AS OF DATE**: 20230323

**DATE AS OF CHANGE**: 20230323

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19731
- **FILM NUMBER:** 23756219

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the <br>Securities Exchange Act of 1934 (Amendment No.)

☑ Filed by the Registrant ☐ Filed by a party other than the Registrant

---

| | |
|:---|:---|
| CHECK THE APPROPRIATE BOX: | CHECK THE APPROPRIATE BOX: |
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☑ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |

---

![](gild4141721_logo.jpg)

**Gilead Sciences, Inc.**

(Name of Registrant as Specified In Its Charter)<br>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

---

| | |
|:---|:---|
| PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): | PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): |
| ☑ | No fee required |
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

---

------

![](gild4141721-defa14a1x1.jpg)

---

| | |
|:---|:---|
|  | Your **Vote** Counts! |
|  | **GILEAD SCIENCES, INC.** |
|  | 2023 Annual Meeting |
|  | Vote by May 2, 2023 |
|  | 11:59 PM ET |
| &nbsp;&nbsp;&nbsp;GILEAD SCIENCES, INC. <br> ATTN: INVESTOR RELATIONS <br> 333 LAKESIDE DRIVE <br> FOSTER CITY, CA 94404 |  |
| &nbsp;&nbsp;V02026-P86584 |  |

---

You invested in GILEAD SCIENCES, INC. and it's time to vote!

 **This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on May 3, 2023, 10:00 a.m. Pacific Time, virtually at www.virtualshareholdermeeting.com/GILD2023.**

Get informed before you vote

You can view the Notice and Proxy Statement, Form 10-K and Supplement online by visiting www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by making a request prior to April 19, 2023. To submit a request for a paper or email copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

---

| | | |
|:---|:---|:---|
| ![](gild4141721-defa14a1x2.jpg) | For complete information and to vote, visit **www.ProxyVote.com** | For complete information and to vote, visit **www.ProxyVote.com** |
| ![](gild4141721-defa14a1x2.jpg) | Control # | ![](gild4141721-defa14a1x3.jpg) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![](gild4141721-defa14a1x4.jpg)<br> **Smartphone users**<br>Point your camera here and<br> vote without entering a<br> control number<br>| &nbsp;&nbsp;&nbsp;&nbsp; ![](gild4141721-defa14a1x5.jpg) <br> **Vote Virtually at the Meeting\***<br>May 3, 2023<br> 10:00 a.m. Pacific Time<br>Virtually at:<br>www.virtualshareholdermeeting.com/GILD2023 |

---

\*Please check the meeting materials for any special requirements for meeting attendance. <br>V1.1

------

**Vote at www.ProxyVote.com**

 **THIS IS NOT A VOTABLE BALLOT**<br>This is an overview of the proposals being presented at the upcoming Annual Meeting. We encourage you to access and review all of the important information contained in the proxy materials before voting. Please follow the instructions on the reverse side to obtain the proxy materials and to vote on these important matters.<br>

---

| | | |
|:---|:---|:---|
| **Voting Items** | **Voting Items** | **Board<br>Recommends** |
| 1. | To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified. |  |
|  | **Nominees:** |  |
| 1a. | Jacqueline K. Barton, Ph.D. | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 1b. | Jeffrey A. Bluestone, Ph.D. | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 1c. | Sandra J. Horning, M.D. | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 1d. | Kelly A. Kramer | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 1e. | Kevin E. Lofton | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 1f. | Harish Manwani | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 1g. | Daniel P. O'Day | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 1h. | Javier J. Rodriguez | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 1i. | Anthony Welters | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 2. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 3. | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. | ![](gild4141721-defa14a2x1b.jpg) **For** |
| 4. | To approve, on an advisory basis, the frequency of future advisory stockholder votes on executive compensation. | ![](gild4141721-defa14a2x3.jpg) **Year** |
| 5. | To approve an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan. | ![](gild4141721-defa14a2x1a.jpg) **For** |
| 6. | To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected. | ![](gild4141721-defa14a2x2.jpg) **Against** |
| 7. | To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting. | ![](gild4141721-defa14a2x2.jpg) **Against** |
| 8. | To vote on a stockholder proposal, if properly presented at the meeting, requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents. | ![](gild4141721-defa14a2x2.jpg) **Against** |
| **Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".** | **Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".** | **Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Sign up for E-delivery".** |

---

V02027-P86584

------